Literature DB >> 6383483

Dual mechanisms involved in development of diverse biological activities of islet-activating protein, pertussis toxin, as revealed by chemical modification of lysine residues in the toxin molecule.

K Nogimori, M Tamura, M Yajima, K Ito, T Nakamura, N Kajikawa, Y Maruyama, M Ui.   

Abstract

Islet-activating protein (IAP), pertussis toxin, is an oligomeric protein composed of an A-protomer and a B-oligomer. There seem to be at least two molecular mechanisms by which IAP exerts its various effects in vivo and in vitro. On the one hand, some of the effects were not significantly affected by acetamidination of the epsilon-amino groups of the lysine residues in the molecule. These include the activities in vitro (1) catalyzing ADP-ribosylation of one of the membrane proteins directly, (2) enhancing membrane adenylate cyclase activity in C6 cells, (3) reversing receptor-mediated inhibition of insulin or glycerol release from pancreatic islets or adipocytes, respectively, and the activities in vivo (4) inhibiting epinephrine-induced hyperglycemia, (5) potentiating glucose-induced hyperinsulinemia, (6) reducing hypertension and increasing the heart rate in genetically hypertensive rats. These activities are concluded to develop as a result of ADP-ribosylation catalyzed by the A-protomer which is rendered accessible to its intramembrane substrate thanks to the associated B-oligomer moiety. Thus, neither the enzymic activity of the A-protomer nor the transporting activity of the B-oligomer needs free amino groups of the lysine residues in the IAP molecule. On the other hand, additional effects of IAP, such as (1) mitogenic, (2) lymphocytosis-promoting, (3) histamine-sensitizing, (4) adjuvant and (5) vascular permeability increasing, were markedly suppressed by acetamidination of the intrapeptide lysine residues. The free epsilon-amino group of lysine would play an indispensable role in the firm (or divalent) attachment of the B-oligomer of IAP to the cell surface that is responsible for development of these activities.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6383483     DOI: 10.1016/0304-4165(84)90072-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  29 in total

1.  Reversal of the CD4(+)/CD8(+) T-cell ratio in lymph node cells upon in vitro mitogenic stimulation by highly purified, water-soluble S3-S4 dimer of pertussis toxin.

Authors:  R Latif; N Kerlero de Rosbo; T Amarant; R Rappuoli; G Sappler; A Ben-Nun
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine.

Authors:  S M Loosmore; G R Zealey; H A Boux; S A Cockle; K Radika; R E Fahim; G J Zobrist; R K Yacoob; P C Chong; F L Yao
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

3.  Lymphocyte receptors for pertussis toxin.

Authors:  C G Clark; G D Armstrong
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

4.  DFT and docking studies of rhodostreptomycins A and B and their interactions with solvated/nonsolvated Mg²⁺ and Ca²⁺ ions.

Authors:  Christiaan Jardínez; Ines Nicolás-Vázquez; Julian Cruz-Borbolla; Cesar A González-Ramírez; Miguel Cepeda; Jose Correa-Basurto; Thangarasu Pandiyan; Rene Miranda
Journal:  J Mol Model       Date:  2013-09-13       Impact factor: 1.810

5.  Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.

Authors:  W N Burnette; J L Arciniega; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

6.  Properties of the B oligomer of pertussis toxin.

Authors:  L Nencioni; M G Pizza; G Volpini; M T De Magistris; F Giovannoni; R Rappuoli
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

7.  Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.

Authors:  J L Arciniega; R D Shahin; W N Burnette; T D Bartley; D W Whiteley; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

8.  Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies.

Authors:  H Sato; Y Sato; I Ohishi
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

9.  Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit.

Authors:  T D Bartley; D W Whiteley; V L Mar; D L Burns; W N Burnette
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  G-protein activation by interleukin 8 and related cytokines in human neutrophil plasma membranes.

Authors:  R W Kupper; B Dewald; K H Jakobs; M Baggiolini; P Gierschik
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.